Figure 1.

IGF2BP2 Is a Target Gene of miR-204 in TC

(A) The intersection of the predicted downstream targets of miR-204 and differentially expressed genes in the GEO: GSE97001 dataset. The five ovals in the figure respectively represent the predicted results and differential analysis results, and the middle part represents the intersection of five groups of data. (B) The differential expression of IGF2BP2 gene in the GEO: GSE97001 dataset. The abscissa represents the sample number, and the ordinate represents the differential expressed gene. Blue boxplot indicates control samples, and red boxplot indicates tumor samples. (C) Differential expression of IGF2BP2 in the TCGA database; red boxplot represents tumor samples, and gray boxplot represents normal samples (∗p < 0.01). (D) Disease-free survival analysis of patients with high (blue line) or low (red line) IGF2BP2 expression in TC. The dotted line indicates 95% confidence interval. (E) The expression patterns of miR-204 and IGF2BP2 in TC cells determined by qRT-PCR, normalized to U6 and GAPDH, respectively. (F) The binding of miR-204 to IGF2BP2 3′ UTR predicted online and confirmed by dual-luciferase reporter gene assay. (G) Transfection efficiency detected by qRT-PCR. (H) Western blot analysis of IGF2BP2 protein levels in cells following miR-204 mimic/inhibitor transfection, normalized to GAPDH. Data (mean ± standard deviation) between two groups were compared with unpaired t test. The experiment was repeated three times independently. ∗p < 0.05. THCA, thyroid cancer.